The forces shaping markets and the economy are often hiding behind a blur of numbers.

So that's why we created The Big Take from Bloomberg Podcasts, to give you the context you need to make sense of it all.

Every day in just 15 minutes, we dive into one global business story that matters.

You'll hear from Bloomberg journalists like Matt Levine.

A lot of this meme stock stuff is, I think, embarrassing to the SEC.

Follow the Big Take podcast on the IHeart Radio app, Apple Podcasts, or wherever you listen.

Welcome to Prognosis. I'm Laura Carlson.

It's day 64 since coronavirus was declared a global pandemic.

Our main story? Many governments and companies were caught off guard by the devastating spread of the coronavirus.

But Gilliad Sciences was different.

The company had vials of its experimental COVID-19 drug Remdesivir ready to put into a clinical

trial.

And it had everything it needed to spring into production when the drug was approved for emergency

use.

How did Gilead anticipate what so many others missed?

But first, here's what happened today.

For the eighth straight week, the number of Americans seeking unemployment totaled in the

millions as the economy continued to reel from the pandemic.

Nearly three million people filed initial jobless claims last week, and while the number

was lower than the week before, it was higher than economists had

predicted. Economists at Goldman Sachs Group revised their forecast for the peak unemployment rate

in the U.S. They now say unemployment will hit 25% before falling again, when they previously

...